EX NOBEL COMMITTEE CHAIRMAN SELECTED FOR NEW SEAT ON DIAMYD MEDICAL’S BOARD
Press Release, Stockholm, Sweden – September 28, 2006 – Diamyd Medical AB (SWEDEN OMXS: DIAM B; USA ADR: DMYDY)Diamyd Medical today announces that Professor Hans Wigzell MD, Ph.D has agreed, pending shareholder approval, to serve as a Director on the Board at Diamyd Medical AB. Having recently presented positive results in a phase II trial in type 1-diabetes patients with the GAD-based therapeutic Diamyd™, the appointment of professor Wigzell brings another experienced advisor to Diamyd as the Company now plans for international clinical trials and continues its discussions with potential